Compare BioNTech SE - ADR (BNTX) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs National Beverage Corp. — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while National Beverage Corp. trades at $30.9 (market cap $2.89B). The key difference: BioNTech SE - ADR is far larger — about 8.1× National Beverage Corp.'s market cap, and BioNTech SE - ADR is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| BNTX | FIZZ | |
|---|---|---|
Market Cap | $23.31B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $46.75 |
52-Week Low | $83.89 | $30.53 |
Enterprise Value | $6.60B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
FIZZ trades at $30.95, down 0.29% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. Revenue has been stable around $1.2B annually, with net income margins improving to 15.56% in 2025. Recent earnings have missed expectations in three of the last four quarters, while the company declared a special dividend of $3.25 per share payable in July 2026.
The outlook is mixed; strong profitability and a reasonable P/E of 15.73 offer value, but stagnant growth and bearish analyst consensus pose risks. The stock's performance hinges on reversing earnings misses and addressing competitive pressures in the beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
